Melanoma Plasma

About Melanoma Plasma

Melanoma Plasma for Tumour Immunology and Liquid Biopsy Research

Melanoma Plasma is collected from IRB-consented donors with a clinically confirmed diagnosis of melanoma and processed within one day of collection to preserve labile analytes including cytokines, soluble receptors, proteins and metabolites. Because plasma is acellular, it is the correct matrix for circulating tumour DNA, soluble immune-checkpoint and secreted-protein work, and Sanguine supplies it in standard or custom aliquot volumes with de-identified clinical annotation for each donor.

Why Melanoma Plasma for Tumour Immunology Research

Melanoma arises from the malignant transformation of melanocytes and is characterised by a high ultraviolet-associated mutational burden, frequent MAPK-pathway driver mutations, and an unusually strong relationship between the tumour and the host immune system. That biology leaves a rich, quantifiable footprint in the circulation.

• Circulating tumour DNA — plasma carries tumour-derived cell-free DNA that can be interrogated for MAPK-pathway driver mutations such as BRAF V600E and NRAS variants, supporting minimal-residual-disease and resistance-tracking assay development.
• Established prognostic serology — lactate dehydrogenase is a well-recognised prognostic marker in advanced melanoma and is measurable in the acellular compartment alongside S100B.
• Soluble immune-checkpoint molecules — soluble PD-L1, PD-1 and CTLA-4 ectodomains circulate and are of direct interest to checkpoint-inhibitor pharmacodynamic programmes.
• Tumour-driven cytokine and chemokine milieu — IL-6, IL-8, IL-10, TNF-α, VEGF and interferon-inducible chemokines reflect tumour-associated inflammation and immune evasion rather than autoimmunity.
• Tumour-derived extracellular vesicles — plasma is the standard source material for exosome and vesicle isolation in melanoma metastasis and immune-modulation studies.
• Immune-related adverse event research — donors treated with checkpoint blockade allow soluble mediators of on-treatment toxicity to be studied in the correct disease context.

Donor Stratification Available

• Stage at collection — localised, regional nodal, and metastatic disease
• Driver mutation status — BRAF-mutant, NRAS-mutant, and BRAF/NRAS wild-type donors where genotyping is documented
• Histological subtype — cutaneous melanoma, plus acral, mucosal and uveal melanoma donors subject to availability
• Treatment status — treatment-naive, on immune-checkpoint inhibitor therapy, on targeted BRAF/MEK inhibitor therapy, or post-treatment
• Response and disease trajectory — responding, progressing, and post-resection disease-free donors; serial draws from the same donor where collected
• Matched healthy controls available, drawn on the same protocol and matched for age, sex and ethnicity

Product Features

• Research Use Only (RUO)
• Plasma collected from clinically confirmed melanoma donors
• Processed within one day of collection
• IRB-approved protocols and informed consent
• Custom aliquot volumes available upon request
• Volumes and anticoagulant options reported per lot

De-identified Donor Data

• Verified melanoma diagnosis
• Demographic data: age, sex assigned at birth, race/ethnicity
• Donor-reported medications, allergies, and comorbidities
• Stage, subtype and treatment context reported per lot where captured
• Additional melanoma-specific metadata available on request

Applications

• Circulating tumour DNA assay development and liquid-biopsy validation
• BRAF and NRAS variant detection sensitivity and limit-of-detection studies
• Soluble immune-checkpoint quantification for checkpoint-inhibitor programmes
• Prognostic biomarker qualification including LDH and S100B workflows
• Multiplex cytokine and chemokine profiling of tumour-associated inflammation
• Plasma proteomic and metabolomic discovery across melanoma stages
• Extracellular-vesicle isolation and cargo characterisation
• Diagnostic reference and control material sourcing for oncology assays

Other Melanoma Specimen Types

• Melanoma Serum
• Melanoma PBMC
• Melanoma Whole Blood
• Melanoma Leukopak

Compliance and Quality Assurance

• IRB-approved and HIPAA-compliant protocols
• Electronic informed consent with 21 CFR Part 11-compliant e-signatures
• Documentation support available for regulatory review

Ordering & Customization

Melanoma plasma is available in standard and custom volumes. For pricing, international orders or documentation requirements, please email learnmore@sanguinebio.com to ensure compatibility with your country’s regulations. To compare collection formats or check wider availability, visit our human plasma page.